By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: More Clinical Research Trials Moving to China
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > More Clinical Research Trials Moving to China
Business

More Clinical Research Trials Moving to China

BarbaraDuck
BarbaraDuck
Share
5 Min Read
SHARE

So many still think that doctors are highly paid positions and that’s not necessary so.  It does cost money and takes time to do research as quoted in this article from Reuters, so they quit.  In the meantime China’s world of clinical trials are growing and some pharma companies said that they can’t afford to conduct trials in the US.

So many still think that doctors are highly paid positions and that’s not necessary so.  It does cost money and takes time to do research as quoted in this article from Reuters, so they quit.  In the meantime China’s world of clinical trials are growing and some pharma companies said that they can’t afford to conduct trials in the US.

Dr. Wes was also talking this week about re-certification to remain board certified in cardiology,for his 2 certifications and then there’s no compensation for any time off work to attend.  To conduct clinical trials of course there’s some certifications involved here depending on the trial.  In other countries income for doctors who do clinical trials do have an increase in income for their time and efforts.  Again with our current healthcare model, if you can call it that in the US, is skewed to where the processes we have and some of the software reporting gets too complicated and too involved to encourage more to participate. 

Also worth a mention is “time” and some are finding it tough enough just to take care of patients without the adding on trials to their already over burdened schedule.  You could almost forget any physician working in a busy hospital environment whether it be a full or part time hospitalist as they have to focus on coding so they would have no time here but on the other hand probably get a better view of patients who would be able to participate as they see everything when admitting.  BD

More Read

Screen Shot 2014-04-01 at 2.49.04 PM
Fundings in Medtech 2009-2014: A Contrarian View
Infographic:Pre-Reform Impact of Self-Pay Patients on US Hospitals
Culture of Disrespect in Medicine Affects Patient Safety
Annual Healthcare Costs For Family of 4 Now At $22,030
Helping Patients Quantify Their Health Data: The Quantified Self Movement

The Hospitalists Have Become The Gatekeepers for Effective Hospital Coding & Sometimes Bear the Burden Alone

Under the surface, however, a growing number of doctors are worried about the tectonic changes in drug research. They resent the export of clinical trial work, which they blame not only on industry’s endless pursuit of lower costs but also on the increasing red tape surrounding trial procedures at home.

“Many of my colleagues have just thrown in the towel and say ‘I’m not going to do clinical research anymore’,” says Dr. Michael Crawford, professor of medicine and chief of clinical cardiology at University of California-San Francisco, one of the top medical schools in the United States.

“It’s pervasive. They’ve just quit clinical trial work. It’s just too difficult and the expenses are so high you end up being in the red when you do a study.”

For now, the world’s emerging economies still play second fiddle to the United States when it comes to testing drugs. Clinicaltrials.org, a website run by the U.S. National Institutes of Health, currently lists more than 106,000 trials around the world, of which just over 50 percent are in the United States. But the balance is shifting, particularly when it comes to the big late-stage trials that really matter in deciding whether a drug is approved for sale. U.S. centers account for only 43 percent of the nearly 19,000 trials in final Phase III testing.

“Drug companies will surely vie for such a market,” says Zhang. “Now, more Chinese can afford to buy Western-made drugs. So instead of performing a trial in China only after completing trials in Europe or the U.S., why not conduct them all at the same time?”

SPECIAL REPORT-Big Pharma’s global guinea pigs | Reuters

 

TAGGED:clinical research trialshealth care business
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

Michael Yoder
BusinessSocial Media

Building a Brand Journalism Team: Michael Yoder [PODCAST]

January 26, 2015
Shannon Morris patient experience
BusinessHospital Administration

Leveraging the Power of Peer Coaches, Role Models and Grassroots Champions

May 10, 2014

Meaningful Use, VNAs, and Addressing the Challenges Each Present

December 18, 2013

Obamacare and the changing healthcare landscape [Infographic]

February 23, 2016
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?